BOSTON, Massachusetts, November 17, 2026
Servier has presented extended follow-up results and subgroup analyses from the Phase 3 INDIGO trial, demonstrating sustained clinical benefit with VORANIGO® (vorasidenib) in patients with Grade 2 IDH-mutant glioma following surgery. The findings were presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia and provide additional insights into long-term disease control, tumor response, seizure outcomes, and quality of life. The updated analyses evaluated patients with mutations in isocitrate dehydrogenase 1 or 2 (IDH1/2), including patients who crossed over from placebo to VORANIGO during the trial. The data strengthen the clinical evidence supporting targeted IDH inhibition and highlight the potential role of molecularly targeted therapies in managing gliomas. Extended follow-up findings from INDIGO build on previously reported clinical results and offer further understanding of treatment outcomes across astrocytoma and oligodendroglioma subgroups.
Extended INDIGO Follow-Up Demonstrates Sustained Clinical Benefit
The extended Phase 3 INDIGO analyses included 144 of the 163 patients originally randomized to placebo who crossed over to VORANIGO by the January 17, 2025, data cutoff. Among crossover patients, investigator-assessed median progression-free survival (PFS) was 37.2 months overall (95% CI, 33.4–not estimable), with a median PFS of 37.2 months in patients with astrocytoma, while median PFS in the oligodendroglioma subgroup had not yet been reached. Patients with progressive disease at crossover had a median PFS of 33.4 months, while median PFS had not been reached in patients without progression at crossover. A post-hoc tumor-volume analysis also showed a change in tumor growth dynamics following treatment initiation, with average tumor volume increasing by 16.1% every six months before crossover and decreasing by 2.9% every six months after crossover. The shift from growth to shrinkage was observed in both astrocytoma and oligodendroglioma subgroups. Additionally, the overall objective response rate assessed by blinded independent review committee increased from 10.7% in September 2022 to 20.8% in January 2025, with improvements also observed across both histological subgroups. These findings provide further insight into the durability of clinical benefit associated with IDH inhibition during extended follow-up.
Exploratory Analyses Highlight Seizure Control and Quality of Life
An exploratory analysis from the INDIGO study evaluated seizure activity and quality of life among participants who experienced at least one seizure during baseline or treatment periods. Between March 2023 and January 2025, the seizure rate among patients receiving VORANIGO decreased from 18.2 to 15.9 seizures per person-year, while the rate ratio versus placebo improved from 0.36 to 0.28, supporting a sustained effect during extended follow-up. The analysis also suggested long-term stabilization of seizure frequency across both oligodendroglioma and astrocytoma subgroups. Quality-of-life assessments demonstrated a lower risk of worsening among patients experiencing more than one seizure who received VORANIGO compared with placebo, based on the Functional Assessment of Cancer Therapy–Brain (FACT-Br) scale and its brain cancer subscale. The reported hazard ratios were 0.38 for FACT-Br and 0.32 for the brain cancer subscale. Although these findings provide encouraging insights into seizure-related outcomes and patient quality of life, the analyses were exploratory and should be interpreted cautiously. The findings offer additional perspectives on the potential impact of targeted treatment on neurological symptoms and patient well-being beyond conventional disease progression measures.
Long-Term Safety Profile Remains Consistent
The extended follow-up demonstrated that the safety profile of VORANIGO remained consistent with earlier analyses, with no new safety signals identified among patients receiving treatment or those who crossed over from placebo. Grade 3 or higher treatment-emergent adverse events occurred in 31.7% of patients randomized to VORANIGO and 20.1% of crossover patients. The most frequently reported severe adverse events included increased alanine aminotransferase (ALT; 10.8% and 7.6%), increased aspartate aminotransferase (AST; 4.8% and 3.5%), seizures (4.8% and 4.2%) and increased gamma-glutamyl transferase (GGT; 3.0% and 0.7%), respectively. No treatment-related deaths were reported in either group, while adverse events leading to treatment discontinuation were uncommon, occurring in 4.8% of patients originally randomized to VORANIGO and 2.1% of crossover patients. These findings add to the long-term safety evidence for vorasidenib and support continued evaluation of targeted IDH inhibition in eligible patients with Grade 2 IDH-mutant glioma. The latest INDIGO analyses reinforce the importance of precision medicine in neuro-oncology, highlighting the potential of molecularly targeted therapies to provide sustained disease control while supporting further investigation into neurological outcomes and quality of life.
Source: Servier press release



